搜尋
Nkarta Inc
NKTX添加自選
3.220USD
+0.370+12.98%
收盤 07/02, 13:00（美東）報價延遲15分鐘
230.38M總市值
虧損本益比TTM
關鍵數據
2.870今開
3.275最高
1.50M成交量
虧損本益比TTM
虧損本益比動
--股利TTM
2.10%換手率
2.850昨收
2.820最低
3.27M成交額
虧損本益比靜
0.81市淨率
0.00%股息率 TTM
-23.72%ROA
3.65052週最高
2.79量比
-108.79M淨利潤
71.55M總股本
-1.3488每股盈餘TTM
0.92Beta
-30.07%ROE
1.63052週最低
15.96%振幅
--毛利率
230.38M總市值
0.64回報/風險
4.49%風險率
TradingKey Nkarta Inc股票評分
單位: USD 更新時間: 2026-07-02操作建議
Nkarta Inc當前公司基本面數據相對謹慎，增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名89/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為11.80。中期看，股價處於上升通道。近一個月，市場表現很強，技術面評分較高，但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Nkarta Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Nkarta Inc亮點
亮點風險
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
估值低估
公司最新PE估值-2.39，處於3年歷史低位
機構減倉
最新機構持股58.52M股，環比減少30.55%
分析師目標
基於
6
分析師
買入
評級
11.800
目標均價
+314.04%
漲幅空間
Nkarta Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Nkarta Inc簡介
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
公司代碼NKTX
公司Nkarta Inc
CEOHastings (Paul J)
網址https://www.nkartatx.com/
相關品種
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
常見問題
Nkarta Inc(NKTX)的當前股價是多少？
Nkarta Inc(NKTX)的當前股價是 3.22。
Nkarta Inc 的股票代碼是什麼？
Nkarta Inc的股票代碼是NKTX。
Nkarta Inc股票的52週最高點是多少？
Nkarta Inc股票的52週最高點是3.65。
Nkarta Inc股票的52週最低點是多少？
Nkarta Inc股票的52週最低點是1.63。
Nkarta Inc的市值是多少？
Nkarta Inc的市值是228.70M。
現在Nkarta Inc(NKTX)的股票是買入、持有還是賣出？
根據分析師評級，Nkarta Inc(NKTX)的總體評級為買入，目標價格為11.80。
Nkarta Inc(NKTX)股票的每股收益（EPS TTM）是多少
Nkarta Inc(NKTX)股票的每股收益（EPS TTM）是-1.41。